Waters Corporation (WAT) - Q2 2004 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended July 3, 2004. Waters Corporation designs, manufactures, and services analytical instruments, including High Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) systems, as well as thermal analysis and rheometry instruments. The company recently expanded into the Laboratory Informatics market through the acquisitions of Creon Lab Control AG (July 2003) and NuGenesis Technologies Corporation (February 2004).
Key Financial Metrics
| Metric | Three Months Ended July 3, 2004 | Six Months Ended July 3, 2004 |
|---|---|---|
| Total Net Sales | $260.5 million | $515.6 million |
| Gross Profit | $154.3 million (59.2% margin) | $301.9 million (58.6% margin) |
| Operating Income | $78.9 million | $129.7 million |
| Net Income | $59.8 million | $100.6 million |
| Diluted EPS | $0.49 | $0.81 |
| Operating Cash Flow (6mo) | $128.1 million | |
| Cash and Equivalents | $420.0 million (as of July 3, 2004) | |
| Total Debt | ~$409.5 million (Notes payable, current/long-term debt) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 12% in the quarter and 14% for the six-month period compared to the prior year. Excluding currency effects, organic growth was 9% for both periods.
- Profitability: Operating income rose 50% in the quarter and 36% for the six-month period. This was significantly aided by a $17.1 million litigation settlement benefit from Perkin-Elmer recorded in the quarter.
- Product Mix: Service sales grew 21% (quarter) and 26% (six months), outpacing product sales growth (9% and 10% respectively), driven by an expanding installed base.
- Acquisitions: Recent acquisitions contributed $5.4 million to quarterly sales and $10.3 million to six-month sales. NuGenesis was acquired for $42.9 million in cash in February 2004.
- Debt and Liquidity: Total borrowings increased to approximately $409.5 million, primarily to fund a $400 million stock repurchase program which was effectively concluded in June 2004. The company repurchased 4.27 million shares for $175 million in the first six months of 2004.
Guidance, Outlook, and Risks
- Product Launches: Shipments of the new ACQUITY UPLC system were postponed to the third quarter for extended testing, with approximately $5.0 million in order backlog as of July 3, 2004.
- Capital Expenditures: The company purchased a 250,000 square foot building for $18.1 million to consolidate facilities. Future capital spending is expected to be modestly higher than 2003 levels.
- Litigation Risks:
- Applera/Perkin-Elmer: Resolved via settlement; $17.4 million received in May 2004.
- Hewlett-Packard (HP): Ongoing patent infringement suits in England, France, and Germany. The company recorded a $7.8 million provision in Q1 2004 for estimated damages in the England and France suits. A trial on damages in the UK was rescheduled to November 2004.
- Outlook: Management expects cash flows and available credit facilities to be sufficient to fund operations, capital spending, and litigation obligations for at least the next 12 months. No dividends are planned.
Investor Verification Checklist
- Litigation Exposure: Verify the status and potential financial impact of the ongoing HP patent litigation in Europe, specifically the rescheduled damages trial.
- Stock Repurchase Impact: Confirm the completion of the $400 million buyback program and the resulting leverage ratio given the increase in debt to ~$410 million.
- Product Pipeline: Monitor the launch timeline and market reception of the ACQUITY UPLC system, which was delayed from Q2 to Q3.
- Acquisition Integration: Assess the revenue contribution and integration progress of the NuGenesis and Creon acquisitions in the Laboratory Informatics sector.
- Currency Sensitivity: Note that reported sales growth included a 3-5% boost from foreign currency translation (Euro, British Pound, Yen); verify organic growth trends excluding these effects.